Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group

Author:

Stetson Peter D.1,McCleary Nadine J.2,Osterman Travis3,Ramchandran Kavitha4,Tevaarwerk Amye5,Wong Tracy6,Sugalski Jessica M.7,Akerley Wallace8,Mercurio Annette9,Zachariah Finly J.9,Yamzon Jonathan9,Stillman Robert C.10,Gabriel Peter E.11,Heinrichs Tricia7,Kerrigan Kathleen8,Patel Shiven B.8,Gilbert Scott M.12,Weiss Everett1

Affiliation:

1. 1Memorial Sloan Kettering Cancer Center, New York, New York;

2. 2Dana-Farber Cancer Institute, Boston, Massachusetts;

3. 3Vanderbilt-Ingram Cancer Center, Nashville, Tennessee;

4. 4Stanford Cancer Institute, Palo Alto, California;

5. 5University of Wisconsin Carbone Cancer Center, Madison, Wisconsin;

6. 6Seattle Cancer Care Alliance, Seattle, Washington;

7. 7National Comprehensive Cancer Network, Plymouth Meeting, Pennsylvania;

8. 8Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah;

9. 9City of Hope National Medical Center, Duarte, California;

10. 10The Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio;

11. 11Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania; and

12. 12Moffitt Cancer Center, Tampa, Florida.

Abstract

Background: Collecting, monitoring, and responding to patient-generated health data (PGHD) are associated with improved quality of life and patient satisfaction, and possibly with improved patient survival in oncology. However, the current state of adoption, types of PGHD collected, and degree of integration into electronic health records (EHRs) is unknown. Methods: The NCCN EHR Oncology Advisory Group formed a Patient-Reported Outcomes (PRO) Workgroup to perform an assessment and provide recommendations for cancer centers, researchers, and EHR vendors to advance the collection and use of PGHD in oncology. The issues were evaluated via a survey of NCCN Member Institutions. Questions were designed to assess the current state of PGHD collection, including how, what, and where PGHD are collected. Additionally, detailed questions about governance and data integration into EHRs were asked. Results: Of 28 Member Institutions surveyed, 23 responded. The collection and use of PGHD is widespread among NCCN Members Institutions (96%). Most centers (90%) embed at least some PGHD into the EHR, although challenges remain, as evidenced by 88% of respondents reporting the use of instruments not integrated. Forty-seven percent of respondents are leveraging PGHD for process automation and adherence to best evidence. Content type and integration touchpoints vary among the members, as well as governance maturity. Conclusions: The reported variability regarding PGHD suggests that it may not yet have reached its full potential for oncology care delivery. As the adoption of PGHD in oncology continues to expand, opportunities exist to enhance their utility. Among the recommendations for cancer centers is establishment of a governance process that includes patients. Researchers should consider determining which PGHD instruments confer the highest value. It is recommended that EHR vendors collaborate with cancer centers to develop solutions for the collection, interpretation, visualization, and use of PGHD.

Publisher

Harborside Press, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3